Study on Dynamic CtDNA Analysis in Pediatric Soft Tissue Sarcoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pediatric soft tissue sarcoma is made up of different subtypes, some of which have distinct genetic alterations. Fusion variants were found in about 43% of bone and soft tissue sarcoma samples. Ewing sarcoma is characterized by recurrent chromosome translocation, with up to 95% of cases showing EWS-ETS translocation. The genetic features of the tumor can change as it spreads or shrinks, and can also be influenced by treatment.

To better understand treatment response and predict relapse early, our study collects liquid samples such as blood, bone marrow, or cerebrospinal fluid at various points during treatment. We then use next-generation sequencing to dynamically monitor the unique genetic profile of the tumor. Additionally, our research may identify new genetic targets and suggest potential treatment options.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas

NCT01567046

Childhood Alveolar Soft-part Sarcoma Childhood Angiosarcoma Childhood Desmoplastic Small Round Cell Tumor +12 more

COMPLETED

The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Lymphoma: A Prospective, Multicenter Clinical Study

NCT04957901

Lymphoma

RECRUITING

Biomarkers in Tissue Samples From Patients With Ewing Sarcoma

NCT01480518

Sarcoma

COMPLETED

Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas

NCT04621201

Diagnosed or Relapsed/Refractory Sarcomas

RECRUITING

Biomarkers in Samples From Young Patients With Soft Tissue Sarcoma

NCT01342783

Sarcoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pediatric Soft Tissue Sarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

detection and monitoring of cirulating tumor DNA

detection and monitoring of cirulating tumor DNA in pediatric soft tissue sarcoma

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (1) pediatric patients with soft tissue sarcoma confirmed by pathology(including but not limited to rhabdomyosarcoma, Ewing sarcoma, BCOR rearrangement undifferentiated sarcoma, CIC rearrangement undifferentiated sarcoma, Epithelioid sarcoma and synovial sarcoma.
* (2)younger than 18 years old.
* (3)ECOG status: PS score0-2.
* (4)measurable lesions on CT/MRI according to RECIST 1.1 criteria : long diameter≥10mm; the longest diameter on ≥ one lymphnode ≥1.5 cm.
* (5)sufficient clinical and pathological information.
* (6)candidates can receive evaluation on time and provide samples during the trials.
* (7)candidates should be informed and provide informed consents.

Exclusion Criteria

* Sufficient samples at baseline point can not be obtained including pre-operation plasma, tissues, bone marrow aspirate and cerebrospinal fluid.
* Plasma samples can not be obtained during monitoring.
* Ineligible candidates at the discretion of researchers.

Minimum Eligible Age

6 Months

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No